Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 1/20 | 0.41 |
| ▸ | PLA2G1B | P04054 | 2/20 | 0.41 |
| ▸ | ATG4B | Q9Y4P1 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | TEAD1 | P28347 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.39 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17356937 | 0.92 | MLYCD (0.45) | MLYCDPLA2G1BATG4BNPC1PKM | |
| SCHEMBL17356977 | 0.86 | TEAD1 (0.38) | HRH3TEAD1 | |
| SCHEMBL17356976 | 0.84 | ROCK2 (0.43) | CARM1PRMT6 | |
| SCHEMBL14703426 | 0.84 | MEN1 (0.52) | MLYCDPLA2G1BATG4BNPC1PKM | |
| SCHEMBL17777580 | 0.82 | HRH4 (0.51) | MLYCDPLA2G1BATG4BNPC1PKM | |
| SCHEMBL14703352 | 0.82 | ALDH1A1 (0.45) | MLYCDPLA2G1BATG4BNPC1PKM | |
| SCHEMBL17356953 | 0.81 | MEN1 (0.47) | KMT2AMEN1CYP1A2CYP3A4GAA | |
| SCHEMBL17356979 | 0.81 | P2RX7 (0.44) | NPC1TSHR | |
| SCHEMBL17777597 | 0.80 | TEAD1 (0.46) | MLYCDPLA2G1BATG4BNPC1PKM | |
| SCHEMBL18197810 | 0.80 | MLYCD (0.41) | MLYCDPLA2G1BATG4BNPC1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10252996-B2 | N1-cyclic amine-N5-substituted biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same | IMMUNOMET THERAPEUTICS INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-20180105494-A1 | N1-CYCLIC AMINE-N5-SUBSTITUTED BIGUANIDE DERIVATIVES, METHODS OF PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HANALL BIOPHARMA CO., LTD. (KP) | 2018-04-19 | — | — | US | disclosed |
| US-20180105494-A1 | N1-CYCLIC AMINE-N5-SUBSTITUTED BIGUANIDE DERIVATIVES, METHODS OF PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HANALL BIOPHARMA CO., LTD. (KP) | 2018-04-19 | — | — | US | disclosed |
| US-9884821-B2 | N1-cyclic amine-N5-substituted biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same | IMMUNOMET THERAPEUTICS INC. (US) | 2018-02-06 | — | — | US | disclosed |
| US-9884821-B2 | N1-cyclic amine-N5-substituted biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same | IMMUNOMET THERAPEUTICS INC. (US) | 2018-02-06 | — | — | US | disclosed |
| US-20150368198-A1 | N1-Cyclic Amine-N5-Substituted Biguanide Derivatives, Methods of Preparing the Same and Pharmaceutical Composition Comprising the Same | IMMUNOMET THERAPEUTICS INC. | 2015-12-24 | — | — | US | disclosed |
| US-20150368198-A1 | N1-Cyclic Amine-N5-Substituted Biguanide Derivatives, Methods of Preparing the Same and Pharmaceutical Composition Comprising the Same | IMMUNOMET THERAPEUTICS INC. | 2015-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368198-A1 | N1-Cyclic Amine-N5-Substituted Biguanide Derivatives, Methods of Preparing the Same and Pharmaceutical Composition Comprising the Same | PRKG1, PRKAG1, PRKG2 | MLYCD 3795/4885PLA2G1B 3417/4885ATG4B 4243/4885 |
| US-10252996-B2 | N1-cyclic amine-N5-substituted biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same | PRKG1, PRKAG1, PRKG2 | MLYCD 3795/4885PLA2G1B 3417/4885ATG4B 4243/4885 |
| US-20180105494-A1 | N1-CYCLIC AMINE-N5-SUBSTITUTED BIGUANIDE DERIVATIVES, METHODS OF PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | PRKG1, PRKAG1, PRKG2 | MLYCD 3795/4885PLA2G1B 3417/4885ATG4B 4243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.